

What are the risks of intracerebral haemorrhage due to alteplase after acute ischaemic stroke? Results from an individual patient data meta-analysis of randomised trials

Dr. William N Whiteley BM BCh,^a Dr. Jonathan Emberson PhD,^b Prof. Kennedy R Lees MD,^c Lisa Blackwell BSc,^b Prof. Gregory Albers, MD,^d Prof. Erich Bluhmki,^e PhD, Prof. Thomas Brott,^f MD, Geoff Cohen, MSc,^a Prof. Stephen Davis,^g MD, Prof. Geoffrey Donnan, MD,^h Dr. James Grotta, MD,ⁱ Prof. George Howard, DrPH,^j Prof. Markku Kaste, MD,^k Dr. Masatoshi Koga, MD,^l Prof. Rüdiger von Kummer,^m Prof. Maarten G Lansberg, MD,^d Prof. Richard I Lindley, MD,ⁿ Prof Patrick Lyden,^o Prof. Jean Marc Olivot, MD,^p Prof. Mark Parsons, MD,^q Prof. Danilo Toni, MD,^r Prof. Kazunori Toyoda, MD,^l Prof. Nils Wahlgren, MD,^s Prof. Joanna Wardlaw, MD,^a Prof. Gregory J del Zoppo, MD,^t Prof. Peter Sandercock DM,^a Prof. Werner Hacke MD,^u Prof. Colin Baigent BM BCh^b

on behalf of the Stroke Thrombolysis Trialists' (STT) Collaboration

Correspondence to:

Professor Colin Baigent

Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU),

Nuffield Department of Population Health

Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, UK

Email: STT@ctsu.ox.ac.uk

Phone: +44 1865 743743

Fax: +44 1865 743985

Word count: Abstract (410); Main text (3636)

- a. University of Edinburgh, Edinburgh, UK
- b. Clinical Trial Service Unit & Epidemiological Studies Unit, University of Oxford, Oxford, UK
- c. University of Glasgow, Glasgow, UK
- d. Stanford University, Stanford, CA, USA
- e. Boehringer Ingelheim, Ingelheim, Germany
- f. Mayo Clinic, Jacksonville, FL, USA
- g. University of Melbourne, Melbourne, VIC, Australia
- h. The Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australia
- i. Memorial Hermann Hospital, Houston, TX , USA
- j. University of Alabama, Birmingham, AL, USA
- k. Clinical Neurosciences, Neurology, University of Helsinki and Department of Neurology,
Helsinki University Hospital, Helsinki, Finland
- l. National Cerebral and Cardiovascular Centre, Suita, Japan
- m. Technische Universität, Dresden, Germany
- n. The George Institute for Global Health, University of Sydney, Sydney, NSW, Australia
- o. Department of Neurology, Cedars-Sinai, Los Angeles, CA, USA
- p. Centre Hospitalier Universitaire de Toulouse, France
- q. University of Newcastle, Newcastle, NSW, Australia
- r. Sapienza University, Rome, Italy
- s. Karolinska Institutet, Clinical Neuroscience, Stockholm, Sweden
- t. University of Washington, Seattle, WA, USA
- u. University of Heidelberg, Heidelberg, Germany

Abstract

Background: Randomised trials have shown that alteplase improves the odds of a good stroke outcome when delivered within 4.5 hours of acute ischaemic stroke. Alteplase also increases the risk of intracerebral haemorrhage, but the factors determining the proportional and absolute risks are uncertain.

Methods: We used data from the Stroke Thrombolysis Trialists' (STT) meta-analysis of individual patient data from 9 randomised trials of alteplase versus placebo (or open control) involving 6,756 patients. We pre-specified assessment of 3 definitions of intracerebral haemorrhage: type 2 parenchymal haemorrhage (PH-2) within 7 days; SITS-MOST haemorrhage within 24-36 hours (PH-2 with at least 4 point deterioration in NIHSS); and fatal intracerebral haemorrhage within 7 days. We used logistic regression, stratified by trial, to model the log odds of intracerebral haemorrhage on allocation to alteplase, treatment delay, age, and stroke severity. Exploratory analyses assessed mortality after intracerebral haemorrhage and examined the absolute risks of intracerebral haemorrhage in the context of functional outcome at 90-180 days.

Findings: Alteplase increased the odds of PH-2 haemorrhage (231/3391 [6.8%] among patients allocated alteplase vs 44/3365 [1.3%] among patients allocated control; odds ratio [OR] 5.55, 95% CI 4.01–7.70; absolute excess 5.5% [95% CI 4.6% - 6.4%]); SITS-MOST haemorrhage (124/3391 [3.7%] vs 19/3365 [0.6%]; OR 6.67, 4.11-10.84; absolute excess 3.1% [2.4% - 3.8%]); and of fatal intracerebral haemorrhage (91/3391 [2.7%] vs 13/3365 [0.4%]; OR 7.14, 3.98–12.79; absolute excess 2.3% [1.7% - 2.9%]). However defined, the proportional increase in intracerebral haemorrhage was similar irrespective of treatment delay, age or baseline stroke severity, but the absolute excess risk of intracerebral haemorrhage increased with increasing stroke severity: for SITS-MOST intracerebral haemorrhage the absolute excess risk ranged from 1.5% (95% CI 0.8-2.6%) for strokes with NIHSS 0-4 to 3.7% (95% CI 2.1-6.3%) for NIHSS ≥ 22 (trend $p=0.01$). For those treated within 4.5 hours, the absolute increase in the proportion (6.8%) achieving a modified Rankin score of 0 or 1 (excellent outcome) exceeded the absolute increase in risk of fatal intracerebral haemorrhage (2.2%) and the increased risk of any death within 90 days (0.9%).

Interpretation: Among patients treated with alteplase the net outcome is predicted both by time to treatment (with faster time increasing the proportion achieving an excellent outcome) and stroke severity (with more severe stroke increasing the absolute risk of intracerebral haemorrhage). Although, on average, within 4.5 hours of stroke, the probability of achieving an excellent outcome clearly exceeds the risk of death, early treatment is especially important for those with severe strokes.

Funding: UK MRC, BHF, University of Glasgow, University of Edinburgh.

1 **Introduction**

2 The Stroke Thrombolysis Trialists' (STT) Collaboration has previously shown, in a meta-analysis of
3 individual participant data from 9 trials of alteplase versus placebo (or open control), that alteplase
4 significantly improves the odds of an excellent outcome (i.e., a modified Rankin score [mRS] of 0 or
5 1) when delivered within 4.5 hours of the onset of ischaemic stroke.¹ However, alteplase increases
6 the risk of intracerebral haemorrhage within 48 hours of administration,¹ and variations in the
7 absolute risks of such haemorrhage according to clinical presentation (eg, stroke severity) may
8 influence the longer term outcome. Recent commentaries have drawn attention to a lack of reliable
9 information about the hazards of alteplase and how they relate to benefits among different groups
10 of patients, particularly those presenting more than 3 hours after stroke onset.^{2,3} In the UK, the
11 Medicines and Healthcare Products Regulatory Agency (MHRA) expert working group considered, in
12 strict confidence, these analyses from the STT Collaboration on the benefits and risks of alteplase as
13 part of its review of the market authorisation for alteplase in acute ischaemic stroke.⁴

14

15 Since there are strong inter-relationships between prognostic variables among the trials included in
16 the STT database (for example, patients treated earlier tended to be older and to have had more
17 severe strokes), an assessment of benefit and harm can only be performed reliably using
18 multivariable models applied to individual participant data. The STT's published protocol⁵ outlined a
19 range of secondary analyses that were to be conducted in addition to the main analysis.¹ The aim of
20 the present report is to describe the results of secondary analyses assessing the proportional and
21 absolute effects of alteplase on the risk of intracerebral haemorrhage and of mortality in different
22 types of patients. We also explore how such variations might influence the net effects of alteplase by
23 90-180 days after stroke.

24

25 **Methods**

26 **Study design**

27 The methods of the Stroke Thrombolysis Trialists' (STT) Collaboration have been described in detail
28 in the published protocol⁵ and in the main report of the primary analysis.¹ Briefly, we sought
29 individual participant data from all completed randomised phase 3 trials of intravenous alteplase in
30 acute ischaemic stroke. Since a systematic review of trials of thrombolysis had been updated in 2013
31 ⁶ we identified potentially eligible trials from that review and by enquiry among active trialists and
32 the manufacturer of alteplase used in all participating trials (Boehringer Ingelheim, Ingelheim,
33 Germany).⁵ We analysed participants in the group to which they were randomly allocated ('intention
34 to treat').

35 **Outcomes**

36 The main outcome of interest in the current analysis was intracerebral haemorrhage, which was
37 defined in three ways:

38 (i) *parenchymal haemorrhage type 2 (PH-2) by 7 days after randomisation*: defined as dense
39 blood clot(s) exceeding 30% of the infarct volume with significant space-occupying effect
40 seen on brain imaging, whether within or remote from the infarct.⁷ For patients from IST-3,⁸
41 in which PH-2 defined solely on radiological findings was not a pre-specified secondary
42 outcome, we approximated it by a report from the IST-3 blinded CT-reading panel of
43 'significant brain parenchymal haemorrhage, local or remote from the infarct, or significant
44 diffuse haemorrhagic transformation of an infarct on brain imaging';

45 (ii) *Safe Implementation of Thrombolysis in Stroke Monitoring Study's (SITS-MOST)*
46 *haemorrhage*⁹ defined as PH-2 on imaging with an increase of 4 NIHSS points or more from
47 baseline (or the lowest point in the first 24 hours) or that led to death within 36 hours of
48 treatment. In the third international stroke trial (IST-3), we approximated the SITS-MOST
49 definition by the occurrence within 24 hours of 'clinically significant deterioration or death,
50 together with evidence of either significant brain parenchymal haemorrhage (local or distant
51 from the infarct) or significant haemorrhagic transformation of an infarct on brain imaging
52 which, in the judgement of the blinded adjudication panel, was likely to have worsened mass
53 effect or contributed to the burden of brain damage'; and

54 (iii) *fatal intracerebral haemorrhage*, defined as PH-2 (or its approximation in IST-3)
55 confirmed by imaging (or autopsy) and death within 7 days of randomisation.

56

57 The timing of brain imaging to detect intracerebral haemorrhage varied slightly across the
58 participating trials. The protocol of each trial mandated imaging at approximately 24 hours post-
59 randomisation and additional brain imaging if neurological deterioration occurred. Further routine
60 brain imaging was performed at 3-5 days in the Echoplanar Imaging Thrombolytic Evaluation Trial
61 (EPITHET),¹⁰ at 1 week in National Institutes of Neurological Diseases and Stroke (NINDS) A and B¹¹
62 and in European Cooperative Acute Stroke Study (ECASS) I, II, and III;^{7,12,13} and at 23-37 days in
63 Alteplase Thrombolysis for Acute Non-interventional Therapy in Ischemic Stroke (ATLANTIS) A and
64 B.^{14,15}

65

66 Analyses of the effect of alteplase on death from all causes within 90 days, both overall and when
67 separated by period of follow-up and treatment delay, have been published previously.¹ In post-hoc
68 analyses of mortality for the current analysis, we subclassified deaths as: “deaths preceded by
69 clinically significant intracerebral haemorrhage” (defined as fatal ICH within 7 days or death
70 following SITS-MOST haemorrhage), and all other deaths.

71

72 We analysed the modified Rankin score (mRS) to define stroke outcome at 3-6 months. We defined
73 an ‘excellent’ stroke outcome as mRS of 0–1 (ie, symptom-free or residual symptoms with no loss of
74 activity), and a very poor stroke outcome as mRS of 5–6 (i.e. bed-bound or dead) at 3–6 months. In
75 IST-3, mRS was reported at 6 rather than 3 months. Therefore, for consistency between the
76 previously published analyses of 90-day mortality and the odds ratio estimates for mRS 0-5 vs 6 in
77 the current analysis, we made the simplifying assumption that IST-3 patients who died between 91
78 days and 6 months (125 [4.1%] IST-3 participants) had an mRS of 5 at 90 days.¹

79

80 **Statistical analysis**

81 We used logistic regression, stratified by trial, to model the common linear dependence of the log
82 odds of intracerebral haemorrhage on allocation to alteplase, treatment delay, age, baseline stroke
83 severity (National Institutes of Health Stroke Scale [NIHSS]) and interactions between allocation to
84 alteplase and each of these other baseline covariates. Alternative hierarchical models that allowed
85 for random effects to operate at the trial level gave virtually identical results. Treatment delay, age
86 and stroke severity were all handled as linear variables. Analyses that considered quadratic risk-
87 relationships for stroke severity were not informative over the models that simply considered a
88 linear term, and are therefore not reported. In addition to such ‘continuous’ analyses, regression

89 models that handled each baseline covariate in pre-defined categories of treatment delay (≤ 3.0
90 hours, >3 to ≤ 4.5 hours, >4.5 hours), age (≤ 80 , >80 years) and stroke severity (NIHSS ≤ 4 , 5-10, 11-15,
91 16-21, ≥ 22) were also employed. Missing 6 month modified Rankin data in IST-3 were imputed from
92 seven-day assessments using an algorithm that was found to work well among patients who had
93 both measurements.⁵ Assessment of whether treatment delay, age, stroke severity or trial modified
94 (individually or jointly) the overall effect of alteplase on particular outcomes was based on the
95 statistical significance of the relevant treatment interactions using likelihood ratio tests (i.e. through
96 comparison of minus twice the log-likelihood statistic between appropriate “nested” models). Trial-
97 by treatment interactions were used to assess whether there were important differences in the odds
98 of intracerebral haemorrhage with alteplase between the 9 trials, and between IST-3 (with open
99 control) and all other (placebo-controlled) trials combined.

100

101 Kaplan-Meier cumulative mortality curves during the first 90 days were calculated for patients
102 allocated alteplase and patients allocated control (crudely pooling across all trials). Subsequently,
103 trial-stratified Cox regression was used to estimate the average mortality hazard ratio within 90 days
104 for ‘deaths preceded by clinically significant intracerebral haemorrhage’ and for all other deaths,
105 with the time to event/censoring for both outcomes set as the earliest of day 90 or the date of
106 death.

107

108 Stroke severity and treatment delay are both important determinants of stroke outcome for patients
109 given alteplase. However, as previously reported, stroke severity and treatment delay were
110 correlated in the included trials.¹ Therefore, to prevent treatment delay from confounding the
111 observed mRS distribution when treated patients were subdivided by their baseline stroke severity
112 (NIHSS ≤ 4 ; 5-10; 11-15; 16-21 and ≥ 22), we compared, for each baseline NIHSS group, the observed
113 mRS distribution for control patients with the *expected* distribution if given alteplase within 3 or
114 within 4.5 hours. This expected distribution was obtained by applying the *overall* odds ratios for each
115 mRS dichotomy (ie, mRS 0 vs 1-6, mRS 0-1 vs 2-6, etc.) within a given time window (≤ 4.5 hours, <3
116 hours or 3-4.5 hours) to the *observed* mRS distribution at 3-6 months among control-allocated
117 patients. Similarly, the estimates of absolute excess risk subdivided by a given characteristic
118 (treatment delay, age or stroke severity) were obtained by applying the overall odds ratio estimates
119 (and their confidence limits) to the control rates that *would have been expected* for that subgroup
120 had average levels of the other two characteristics applied.

121

122

123 All estimates of treatment effect are provided with their 95% confidence intervals with p-values
124 considered conventionally statistically significant, without allowance for multiple testing, at the 5%
125 significance level. Analyses were done with SAS version 9.3 (SAS Institute, Cary) and R version 2.11.1
126 (www.R-project.org).

127

128 **Role of the funding source**

129 The funders had no role in study design, data collection, data analysis, data interpretation, or writing
130 of the report. The secretariat had full access to all the data and responsibility for the decision to
131 submit for publication.

132

133 **Results**

134 Data were available from 6756 participants in 9 trials of intravenous alteplase versus control
135 (webtable 1). Baseline data on treatment delay, age and baseline NIHSS were complete for almost all
136 participants (6602/6756, 98%). Individual participant data were sought from an additional 5 trials^{16–}
137 ²⁰ involving 270 participants, which reported a total of 18 patients with intracerebral haemorrhage
138 (11 alteplase versus 7 control), but were either not available or, in one case,¹⁸ the authors could not
139 be contacted.

140 Overall, 275 participants had a PH-2 haemorrhage within 7 days of treatment (38% [39% alteplase vs
141 30% control] fatal within 7 days), of which 52% were SITS-MOST haemorrhages (41% [40% vs 47%]
142 fatal within 7 days). After adjusting for age, treatment delay and stroke severity, alteplase increased
143 the odds of intracerebral haemorrhage by a factor of about 6 to 7, depending on the definition used:
144 PH-2 haemorrhage: 231/3391 (6.8%) vs 44/3365 (1.3%); OR 5.55, 95% CI 4.01–7.70; SITS-MOST
145 haemorrhage 124/3391 (3.7%) vs 19/3365 (0.6%); OR 6.67, 4.11–10.84; and fatal intracerebral
146 haemorrhage within 7 days 91/3391 (2.7%) vs 13/3365 (0.4%); OR 7.14, 3.98–12.79 (figure 1). These
147 odds ratios were similar after adjusting for other baseline variables recorded and available in the
148 data provided (prior stroke/TIA, prior diabetes, antiplatelet use, weight and systolic blood pressure
149 at randomisation, data not shown). There was no evidence that the odds ratios for any of the
150 definitions of intracerebral haemorrhage differed between trials, or between IST-3 (which had open
151 control) and the 8 placebo-controlled trials (all heterogeneity p-values >0.05, webfigure 1). The
152 proportion of patients with PH-2 haemorrhages who died by 7 days was also similar in IST-3 (62/159,
153 [39%]) and in the other 8 (placebo-controlled) trials (42/116, [36%]).

154 For each type of intracerebral haemorrhage, the proportional effects of alteplase were similar
155 irrespective of time to treatment, age or stroke severity (webfigures 2-4; p-values for interaction all
156 >0.05). The estimated absolute excess risks were similar irrespective of time to treatment and age,

157 but there was a trend towards larger absolute excess risks with increasing stroke severity for PH-2
158 haemorrhage ($p < 0.0001$; webfigure 5), fatal intracerebral haemorrhage ($p = 0.0002$; webfigure 6) and
159 SITS-MOST haemorrhage ($p = 0.0101$; figure 2). For SITS-MOST intracerebral haemorrhages (ie,
160 clinically significant bleeds in which there was both radiological evidence of bleeding and worsening
161 symptoms within 24-36 hours after treatment), the absolute excess risk over control increased from
162 1.5% (95% CI 0.8-2.6%) among those with mild strokes (baseline NIHSS 0–4) to 3.7% (95% CI 2.1-
163 6.3%) in patients with NIHSS ≥ 22 (figure 2).

164 Cause of death was not widely available in participating trials, but we conducted exploratory
165 analyses to assess the 90-day risks of 'death preceded by clinically significant intracerebral
166 haemorrhage' and of all other deaths. Among all trial participants, allocation to alteplase was
167 associated with a significant increase in the risk of a death preceded by clinically significant
168 intracerebral haemorrhage within 90 days (118 [3.5%] vs 14 [0.4%]; HR 8.52, 4.89-14.82; figure 3).
169 Such deaths were, however, offset by non-significantly fewer deaths among people dying who had
170 not experienced such a haemorrhage (490 [14.5%] vs 542 [15.9%]; HR 0.92, 95% CI 0.82-1.04; figure
171 3). An analysis that defined clinically significant haemorrhage by the radiological appearance of a
172 PH2 haemorrhage, rather than by the SITS-MOST definition, gave similar results (webfigure 8).

173

174 Since the estimated absolute excess risk of intracerebral haemorrhage increased incrementally
175 within the 5 pre-specified categories of stroke severity, we assessed the impact of this trend on the
176 expected distribution of mRS scores at 90 days among all patients treated within 4.5 hours (on
177 average, at 3 hours and 20 minutes) by applying the odds ratio for each mRS transition to the control
178 population (figure 4 and 5). Among patients with the mildest strokes (NIHSS 0–4), alteplase would be
179 expected to result in an absolute increase in excellent outcome of 8.0% (95% CI 4.5-11.1), and to
180 reduce the absolute risk of very poor outcome by 0.1% (95% CI -0.6-0.8; 0.3% reduction in severe
181 disability [mRS 5] and 0.2% excess of death). For the most severe strokes (NIHSS ≥ 22), the

182 corresponding amounts were a 1.0% (95% CI 0.5-1.5) absolute increase in excellent outcome and a
183 0.6% reduction in very poor outcome (95% CI -2.3-4.1; 2.8% reduction in severe disability and 2.1%
184 excess of death).

185 Discussion

186 Within the 9 trials studied, alteplase resulted in approximately 6 to 7 times the odds of intracerebral
187 haemorrhage within the first 7 days, which was similar irrespective of treatment delay, age and
188 stroke severity. In these trials the underlying risk of intracerebral haemorrhage without alteplase
189 increased with stroke severity, which is consistent with a systematic review of 55 observational
190 studies in which each 1 point increment in the NIHSS was associated with an 8% (95% CI 6-11%)
191 increase in the odds of intracerebral haemorrhage ($p < 0.001$).²¹ In the absence of heterogeneity of
192 the odds ratio for haemorrhage, therefore, the absolute excess risk of intracerebral haemorrhage
193 was higher among those with more severe strokes. Overall, among all patients, alteplase resulted in
194 a 2.3% absolute excess of fatal intracerebral haemorrhage during the first week (Figure 1). After the
195 first week, deaths preceded by ICH remained elevated among those allocated alteplase (Figure 3),
196 perhaps due to conditions associated with chronic immobility (eg pneumonia). By contrast, during
197 the first 90 days, there were non-significantly fewer other deaths among alteplase-allocated
198 patients, perhaps owing to the beneficial effects of alteplase on functional outcome.

199

200 Taken together, the present analyses and our previous report show that, when given within 4.5
201 hours, alteplase is associated with an early hazard due to intracerebral haemorrhage but a later
202 benefit in terms of less disability, and this study raises the hypothesis that there is a lower risk of
203 death among those not experiencing an intracerebral haemorrhage. This pattern is analogous to
204 many surgical procedures, eg carotid endarterectomy, where there is an early surgical hazard
205 followed by a later survival benefit in selected patients^{22,23} and the balance of hazard and benefit
206 among particular types of patients determines their net clinical outcome.

207

208 The net effects of alteplase among particular types of patients are best represented by the predicted
209 shift in the distribution of modified Rankin Scores among patients allocated to alteplase and control.

210 Our previous analyses indicated that the benefits of alteplase diminish with increasing treatment
211 delay, whilst the present analyses indicate that the absolute excess risk of intracerebral
212 haemorrhage increases with stroke severity. Our exploratory analyses suggest that these two
213 variables help determine the net effects of alteplase in particular patients. In particular, they may
214 help to explain the observation in our previous report¹ that there was a non-significant trend
215 towards a larger relative increase in 90 day mortality among those treated later. Although there
216 were limited data in the 3-4.5 hour group, it may be hypothesised that the observed patterns are
217 due to the shifting balance between (i) an early increase in mortality from intracerebral
218 haemorrhage (which is of similar magnitude irrespective of delay) and (ii) reduced mortality due to
219 salvaged brain tissue among those treated early, with the magnitude of this benefit diminishing as
220 delay increases (ie, 'time is brain').

221

222 There is a need for improved representations of the benefits and risks of alteplase, building on those
223 developed previously²⁴⁻²⁷, to better equip clinicians in discussions with patients and their family
224 members. Figure 4 and webfigures 7a and 7b have the inherent limitation that they do not directly
225 represent the additional risks of fatal intracerebral haemorrhage. An alternative example of a
226 possible representation of the expected effects of alteplase on the distribution of mRS scores,
227 subdivided by stroke severity, is shown in Figure 5. Each cell represents a hypothetical group of 100
228 typical patients with an ischaemic stroke of given severity, with colours indicating a gradation of mRS
229 scores at 3-6 months after stroke from excellent outcome (red circles, mRS 0-1) through to very poor
230 outcome (mRS 5-6). Fatal intracerebral haemorrhage is marked by a purple circle with a cross. From
231 this figure, a patient can see, in their particular case, the expected impact of being given alteplase,
232 since a comparison of left (untreated) and right (treated) cells shows both the expected shift in mRS
233 outcomes and the risk associated with intracerebral haemorrhage. Further development and
234 refinement of the representation in figure 5 is now needed to provide a useful tool for clinicians.

235

236 Recent trials have demonstrated that intra-arterial thrombectomy in addition to intravenous
237 thrombolysis leads to improved outcomes²⁸⁻³² among those with large artery ischaemic stroke and
238 documented proximal arterial occlusion, which may help to improve the ratio of benefit to risk by
239 magnifying benefit through improved salvage of brain tissue. Alternatively, it may be possible to
240 improve this ratio by reducing the risk of intracerebral haemorrhage with intravenous thrombolytic
241 therapy, for example, by the use of tenecteplase as an alternative to alteplase^{33,34}, use of a lower
242 dose of alteplase (0.6mg/kg),³⁵ or by targeting thrombolysis based on neuroimaging appearances.³¹

243

244 Although our analyses provide a general guide to the effects of alteplase in different types of
245 patients, there are a number of potential limitations: First, and most importantly, despite having
246 access to individual participant data from 9 trials in almost 7000 patients with acute ischaemic
247 stroke, there were relatively small numbers of outcomes with which to examine treatment effects in
248 different patient subgroups.³² Whilst recognising that there is a need to provide better information
249 for doctors and patients, it is important that treatment decisions take account both of statistical
250 uncertainty and of the possibility that different patients and their families may reach different
251 decisions when presented with the same data on expected outcomes. The second limitation was
252 that the methods employed by the Third International Stroke Trial (IST-3) differed in several respects
253 to the other trials. It lacked a placebo control, raising the potential of biased reporting if there was a
254 greater tendency to investigate possible intracerebral haemorrhage in the alteplase arm. However,
255 alteplase increased the odds of intracerebral haemorrhage to a similar extent in IST-3 and in other
256 trials (webfigure 1), suggesting that any bias due to the open nature of IST3 was small. The IST3 trial
257 also did not record PH-2 haemorrhages or SITS-MOST haemorrhages, but defined equivalent
258 categories. In the future, any such limitations caused by different symptomatic haemorrhage

259 definitions and classifications may be mitigated by the use of the recent Heidelberg classification of
260 intracerebral bleeding events.³⁹

261

262 A third limitation was that we did not have cause of death available, but could only examine the
263 effects of alteplase on deaths that followed a haemorrhage. Our data strongly suggest, however,
264 that most early deaths following a PH2 haemorrhage were likely to be due to the haemorrhage. In
265 particular, the increased risk of death from any cause by 7 days (absolute excess 2.2%)¹ is virtually
266 identical to the increased risk of those deaths that followed a PH2 haemorrhage (2.3%) (Figure 1). In
267 addition, death preceded by clinically significant haemorrhage remained elevated after the first
268 week (Figure 3). The most likely explanation for these large mortality differences is that
269 haemorrhage led to death in almost all such cases (either directly, or after withdrawal of medical
270 intervention), since the alternative explanation – that alteplase-allocated patients were at least 7
271 times more likely than control-allocated patients to die from causes unrelated to the bleed – seems
272 highly implausible given their similar prognostic scores at randomization and the lack of any other
273 known hazard of alteplase.

274

275 Finally, we were limited in the extent to which we could evaluate the effect of other potential risk
276 factors, such as blood glucose and blood pressure control, that have previously been associated with
277 increased bleeding risk after alteplase administration, and nor could we assess the effects of
278 alteplase on less severe intracerebral haemorrhage since the requisite data were not consistently
279 available.

280

281

282 **Conclusion**

283 Although alteplase increases the early risk of haemorrhagic stroke, when given within 4.5 hours the
284 proportion of patients experiencing an excellent outcome exceeded the proportion dying from
285 intracerebral haemorrhage. The greatest absolute risk of intracerebral haemorrhage after alteplase
286 is experienced by those with the most severe strokes, among whom prompt treatment is essential in
287 order to achieve worthwhile benefit.
288

289 **Contributors**

290 WH and EB had the original idea for this meta-analysis and implemented data definitions in 2004;
291 KRL and EB refined the approach in 2010; CB, PS, and JW had the idea for this cycle of the meta-
292 analysis and all authors contributed to the subsequent study protocol and statistical analysis plan. All
293 authors contributed either to the acquisition of the original trial data or the creation of the
294 combined dataset. JE and LB did the statistical analysis. WW wrote the first draft of the report. All
295 authors contributed to the interpretation of the results, revision of the report, and have approved
296 the final version of the manuscript.

297 **Included trials**

298 ATLANTIS A and B (Gregory Albers, James Grotta, Maarten Lansberg, Jean Marc Olivot); ECASS-1,
299 ECASS-2, ECASS-3 (Erich Bluhmki, Werner Hacke, Markku Kaste, Kennedy Lees, Rüdiger von Kummer,
300 Danilo Toni, Nils Wahlgren); EPITHET (Stephen Davis, Geoffrey Donnan, Mark Parsons); IST-3 (Peter
301 Sandercock, Joanna Wardlaw, Richard Lindley, Geoff Cohen, William Whiteley); NINDS A and B
302 (Thomas Brott, James Grotta, Patrick Lyden).

303 **STT Statistical Analysis Centre and Secretariat**

304 Colin Baigent, Lisa Blackwell, Erich Bluhmki, Kelly Davies, Jonathan Emberson, Heather Halls, Lisa
305 Holland, George Howard, Clare Mathews, Samantha Smith, Kate Wilson.

306 **Declaration of interests**

307 CB, LB, and JE have not accepted fees, honoraria, or paid consultancies but are involved in clinical
308 trials of lipid-modifying treatment funded by Merck to the University of Oxford, with the University
309 the trial sponsor in all cases. KRL has received speaker fees from and has served on the data
310 monitoring committee of trials for Boehringer Ingelheim; his department has received research
311 grant support from Genentech. GA has received research grant support from Lundbeck, fees for
312 consultancy and advisory board membership from Lundbeck, Covidien, Codman, and Genentech,
313 fees for acting as an expert witness, and owns stock in iSchemaView. EB is employed by Boehringer
314 Ingelheim. SD has received honoraria from Boehringer Ingelheim, EVER Pharma, and Sanofi and has
315 received fees for consultancy and advisory board membership from Boehringer Ingelheim and
316 Sanofi. GD has received research grant support from the NHMRC (Australia) and honoraria from
317 Pfizer and Bristol-Myers Squibb. JG has received fees for consultancy and advisory board
318 membership from Lundbeck. RvK has received speaker fees and honoraria from Penumbra and
319 Lundbeck. RIL has received honoraria from Boehringer Ingelheim and Covidien. JMO has received
320 speaker fees from Boehringer Ingelheim. MP has received travel support from Boehringer Ingelheim.
321 DT has received speaker fees and fees for consultancy and advisory board membership from
322 Boehringer Ingelheim and Bayer. KT has received research grant support from the Ministry of Health,
323 Labour, and Welfare of Japan, and speaker fees from Mitsubishi Tanabe Pharma. JW has received
324 research grant support from the UK Medical Research Council and from Boehringer Ingelheim to the
325 University of Edinburgh for a research scanner bought more than 10 years ago. NW is chairman of
326 SITS International which receives an unrestricted grant from Boehringer Ingelheim. WW has received
327 research grant support from the UK Medical Research Council. PS has received honoraria for lectures
328 which were paid to the department from Boehringer Ingelheim. WH has received research grant
329 support from Boehringer Ingelheim, and speaker fees and fees for consultancy and advisory board
330 membership from Boehringer Ingelheim. PL, TB, GC, GH, MKa, MKo, ML, NW, and GJdZ declare no
331 competing interests.

332 **Acknowledgments**

333 This collaboration is coordinated by the Clinical Trial Service Unit & Epidemiological Studies Unit at
334 the University of Oxford, UK. The Unit receives core funding from the UK Medical Research Council
335 and the British Heart Foundation. This work also received support from the University of Glasgow
336 and University of Edinburgh.

337 **Figure legends**

338 **Figure 1:** The effect within 7 days of alteplase on three types of intracerebral haemorrhage (ICH):
339 parenchymal haemorrhage type 2 (PH-2), SITS-MOST haemorrhage, and fatal ICH.

340 **Figure 2:** The effect of alteplase on SITS-MOST intracerebral haemorrhage at 24 to 36 hrs by time to
341 treatment, age and stroke severity.

342 **Figure 3** The effect of alteplase on deaths following clinically significant intracerebral haemorrhage
343 (fatal haemorrhage within 7 days or death following SITS-MOST haemorrhage), and all other deaths,
344 during the first 90 days, overall and by period of follow up.

345 **Figure 4** Expected proportions in each category of modified Rankin score at 3—6 months, with or
346 without alteplase given within 4.5 hours of symptom onset. mRS 0–1 indicates survival symptom-
347 free or with residual symptoms with no loss of activity; mRS 5-6 indicates bed-bound or dead at 3–6
348 months.

349 **Figure 5** Expected stroke outcome at 3-6 months for groups of patients: i) not treated with alteplase;
350 ii) treated with alteplase within 3 hours of stroke onset; and iii) treated with alteplase between 3
351 and 4.5 hours after stroke onset. mRS 0–1 indicates survival symptom-free or residual symptoms
352 with no loss of activity; mRS 5-6 indicates bed-bound or dead at 3–6 months.

353

354

355

356

357

358

359

360

361

362

363 **Research in Context**

364 *Evidence before this study*

365 Meta-analyses have previously shown that alteplase increases the risk of intracerebral haemorrhage,
366 but the extent to which the absolute excess risk differs by haemorrhage type, stroke severity, age, or
367 treatment delay was uncertain, as was the balance between the risk of intracerebral haemorrhage
368 and treatment benefit in different patients. We used individual participant data from 9 trials of
369 alteplase versus control in the Stroke Thrombolysis Trialists' Collaboration to provide meta-analyses
370 of the available evidence.

371 *Added value of this study*

372 This study provides estimates of symptomatic intracerebral haemorrhage risk, and benefits due to
373 alteplase, in patients grouped by stroke severity, age and treatment delay. With the individual
374 participant data, we were able to adjust for complex inter-correlations between variables to produce
375 reliable estimates of absolute treatment effects.

376 *Implications of all the available evidence*

377 The absolute benefits of alteplase decline with treatment delay, and the absolute harms due to
378 alteplase (from intracranial haemorrhage) increase with stroke severity. When delivered within 4.5
379 hours, the proportion of patients experiencing a good outcome exceeds those dying from
380 intracranial haemorrhage. However, because the risk of haemorrhage is highest in those with the
381 most severe stroke, prompt treatment of these patients is especially important. These absolute risk
382 estimates will be useful to communicate the effects of alteplase to patients, families and clinicians.

References

- 1 Emberson J, Lees KR, Lyden P, *et al.* Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. *Lancet* 2014; **384**: 1929–35.
- 2 Shinton R. Questions about authorisation of alteplase for ischaemic stroke. *Lancet* 2014; **384**: 659–60.
- 3 Alper BS, Malone-Moses M, McLellan JS, Prasad K, Manheimer E. Thrombolysis in acute ischaemic stroke: time for a rethink? *BMJ* 2015; **350**: h1075.
- 4 Medicines and Healthcare products Regulatory Agency. Alteplase for treatment of acute ischaemic stroke: independent review. <https://www.gov.uk/government/publications/alteplase-for-treatment-of-acute-ischaemic-stroke-independent-review>. 2015. <https://www.gov.uk/government/publications/alteplase-for-treatment-of-acute-ischaemic-stroke-independent-review> (accessed July 24, 2015).
- 5 STTC. Details of a prospective protocol for a collaborative meta-analysis of individual participant data from all randomized trials of intravenous rt-PA vs. control: statistical analysis plan for the Stroke Thrombolysis Trialists' Collaborative meta-analysis. *Int J Stroke* 2013; **8**: 278–83.
- 6 Wardlaw JM, Murray V, Berge E, *et al.* Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. *Lancet* 2013; **379**: 2364–72.
- 7 Hacke W, Kaste M, Fieschi C, *et al.* Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Hemispheric Stroke. *JAMA* 1995; **274**: 1017–25.
- 8 IST-3 collaborative group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. *Lancet* 2012; **379**: 2352–63.
- 9 Wahlgren N, Ahmed N, Davalos A, *et al.* Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. *Lancet* 2007; **369**: 275–82.
- 10 Davis SM, Donnan GA, Parsons MW, *et al.* Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. *Lancet Neurol* 2008; **7**: 299–309.
- 11 The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue Plasminogen Activator for Acute Ischemic Stroke. *N Engl J Med* 1995; **333**: 1581–8.
- 12 Hacke W, Kaste M, Fieschi C, *et al.* Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). *Lancet* 1998; **352**: 1245–51.
- 13 Hacke W, Kaste M, Bluhmki E, *et al.* Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke. *N Engl J Med* 2008; **359**: 1317–29.
- 14 Albers GW, Clark WM, Madden KP, Hamilton SA. ATLANTIS trial: results for patients treated within 3 hours of stroke onset. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. *Stroke* 2002; **33**: 493–5.
- 15 Clark WM, Wissman S, Albers GW, *et al.* Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset. *JAMA* 1999; **282**: 2019–26.
- 16 Haley EC, Brott TG, Sheppard GL, *et al.* Pilot randomized trial of tissue plasminogen activator

- in acute ischemic stroke. The TPA Bridging Study Group. *Stroke* 1993; **24**: 1000–4.
- 17 Mori E, Yoneda Y, Tabuchi M, *et al.* Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. *Neurology* 1992; **42**: 976–82.
 - 18 Wang S, Wang X, Zeng H, *et al.* Early intravenous thrombolysis with recombinant tissue plasminogen activator for acute cerebral infarction. *Chinese Crit care Med* 2003; **15**: 542–5.
 - 19 Yamaguchi T, Hayakawa T, Kiuchi H. Intravenous Tissue Plasminogen Activator Ameliorates the Outcome of Hyperacute Embolic Stroke. *Cerebrovasc Dis* 1993; **3**: 269–72.
 - 20 Hemmen TM, Raman R, Guluma KZ, *et al.* Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke (ICTuS-L): final results. *Stroke* 2010; **41**: 2265–70.
 - 21 Whiteley WN, Slot KB, Fernandes P, *et al.* Risk Factors for Intracranial Hemorrhage in Acute Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen Activator: A Systematic Review and Meta-Analysis of 55 Studies. *Stroke* 2012; **43**: 2904–9.
 - 22 ECST. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). *Lancet* 1998; **351**: 1379–87.
 - 23 NASCET. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. *N Engl J Med* 1991; **325**: 445–53.
 - 24 Gadhia J, Starkman S, Ovbiagele B, Ali L, Liebeskind D, Saver JL. Assessment and improvement of figures to visually convey benefit and risk of stroke thrombolysis. *Stroke* 2010; **41**: 300–6.
 - 25 Flynn D, Nesbitt DJ, Ford GA, *et al.* Development of a computerised decision aid for thrombolysis in acute stroke care. *BMC Med Inform Decis Mak* 2015; **15**: 6.
 - 26 Kent DM, Ruthazer R, Decker C, *et al.* Development and validation of a simplified Stroke-Thrombolytic Predictive Instrument. *Neurology* 2015; **85**: 942–9.
 - 27 Decker C, Chhatriwalla E, Gialde E, *et al.* Patient-Centered Decision Support in Acute Ischemic Stroke: Qualitative Study of Patients' and Providers' Perspectives. *Circ Cardiovasc Qual Outcomes* 2015; **8**: S109–16.
 - 28 Jovin TG, Chamorro A, Cobo E, *et al.* Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke. *N Engl J Med* 2015; **372**: 2296–306.
 - 29 Campbell BCV, Mitchell PJ, Kleinig TJ, *et al.* Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection. *N Engl J Med* 2015; **372**: 1009–18.
 - 30 Berkhemer OA, Fransen PSS, Beumer D, *et al.* A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke. *N Engl J Med* 2014; **372**: 1009–18.
 - 31 Goyal M, Demchuk AM, Menon BK, *et al.* Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke. *N Engl J Med* 2015; **372**: 2285–95.
 - 32 Saver JL, Goyal M, Bonafe A, *et al.* Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke. *N Engl J Med* 2015; **372**: 2285–95.
 - 33 Huang X, Cheripelli BK, Lloyd SM, *et al.* Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. *Lancet Neurol* 2015; **14**: 368–76.
 - 34 Parsons M, Spratt N, Bivard A, *et al.* A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. *N Engl J Med* 2012; **366**: 1099–107.
 - 35 Huang Y, Sharma VK, Robinson T, *et al.* Rationale, design, and progress of the ENhanced Control of Hypertension ANd Thrombolysis strokeE stuDy (ENCHANTED) trial. *Int J Stroke* 2015; **10**: 778–88.
 - 36 IST-3 collaborative group. Association between brain imaging signs, early and late outcomes,


- and response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial (IST-3): secondary analysis of a randomised controlled trial. *Lancet Neurol* 2015; **14**: 485–96.
- 37 Bentley P, Ganesalingam J, Carlton Jones AL, *et al*. Prediction of stroke thrombolysis outcome using CT brain machine learning. *Neuroimage Clin* 2014; **4**: 635–40.
- 38 Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. *Health Technol Assess* 2001; **5**: 1–56.
- 39 von Kummer R, Broderick JP, Campbell BCV, *et al*. The Heidelberg Bleeding Classification. *Stroke* 2015; **46**: 2981–6.

Table 1: Baseline characteristics of participating trials

Variable	NINDS A ¹¹	NINDS B ¹¹	ECASS I ⁷	ECASS II ¹²	ATLANTIS A ¹⁵	ATLANTIS B ¹⁴	ECASS III ¹³	EPITHET ¹⁰	IST-3 ⁸	TOTAL
Number randomized	291	333	620	800	142	613	821	101	3035	6756
Alteplase	144 (49%)	168 (50%)	313 (50%)	409 (51%)	71 (50%)	301 (49%)	418 (51%)	52 (51%)	1515 (50%)	3391 (50%)
Control	147 (51%)	165 (50%)	307 (50%)	391 (49%)	71 (50%)	312 (51%)	403 (49%)	49 (49%)	1520 (50%)	3365 (50%)
Treatment delay (hours)	2.0 (0.6)	2.0 (0.6)	4.4 (1.1)	4.3 (1.1)	4.3 (1.1)	4.4 (0.8)	4.0 (0.4)	4.9 (0.8)	4.2 (1.2)	4.0 (1.2)
>0, ≤3	290 (>99%)	333 (100%)	87 (14%)	158 (20%)	22 (15%)	39 (6%)	-	-	620 (20%)	1549 (23%)
>3, ≤4.5	1 (<1%)	-	233 (38%)	265 (33%)	53 (37%)	249 (41%)	788 (96%)	31 (31%)	1148 (38%)	2768 (41%)
>4.5	-	-	295 (48%)	370 (46%)	67 (47%)	321 (52%)	6 (1%)	69 (68%)	1266 (42%)	2394 (35%)
Missing	-	-	5 (1%)	7 (1%)	-	4 (1%)	27 (3%)	1 (1%)	1 (<1%)	45 (1%)
Age (years)	66 (11)	68 (12)	65 (12)	66 (11)	66 (13)	66 (11)	65 (12)	72 (13)	77 (12)	71 (13)
≤ 80	279 (96%)	289 (87%)	615 (>99%)	792 (99%)	142 (100%)	608 (>99%)	805 (98%)	76 (75%)	1418 (47%)	5024 (74%)
>80	12 (4%)	44 (13%)	5 (1%)	8 (1%)	-	3 (<1%)	15 (2%)	25 (25%)	1617 (53%)	1729 (26%)
Missing	-	-	-	-	-	2 (<1%)	1 (<1%)	-	-	3 (<1%)
Stroke severity (NIHSS)	14 (7)	15 (7)	12 (6)	12 (6)	13 (7)	11 (6)	10 (5)	13 (6)	12 (7)	12 (7)
>0, ≤4	16 (5%)	13 (4%)	34 (5%)	47 (6%)	10 (7%)	47 (8%)	98 (12%)	1 (1%)	400 (13%)	666 (10%)
>4, ≤10	78 (27%)	98 (29%)	189 (30%)	339 (42%)	57 (40%)	279 (46%)	389 (47%)	40 (40%)	1064 (35%)	2533 (37%)
>10, ≤15	68 (23%)	63 (19%)	183 (30%)	232 (29%)	28 (20%)	128 (21%)	163 (20%)	22 (22%)	601 (20%)	1488 (22%)
>15, ≤21	76 (26%)	78 (23%)	146 (24%)	113 (14%)	25 (18%)	106 (17%)	142 (17%)	29 (29%)	618 (20%)	1333 (20%)
>21	45 (15%)	74 (22%)	28 (5%)	43 (5%)	20 (14%)	33 (5%)	18 (2%)	9 (9%)	352 (12%)	622 (9%)
Missing	8 (3%)	7 (2%)	40 (6%)	26 (3%)	2 (1%)	20 (3%)	11 (1%)	-	*	114 (2%)
Female	120 (41%)	142 (43%)	231 (37%)	331 (41%)	45 (32%)	250 (41%)	325 (40%)	43 (43%)	1570 (52%)	3057 (45%)
History of hypertension	188 (65%)	220 (66%)	258 (42%)	412 (52%)	87 (61%)	364 (59%)	514 (63%)	71 (70%)	1954 (64%)	4068 (60%)
History of stroke	49 (17%)	34 (10%)	83 (13%)	158 (20%)	31 (22%)	89 (15%)	89 (11%)	11 (11%)	699 (23%)	1243 (18%)
History of diabetes mellitus	64 (22%)	67 (20%)	81 (13%)	169 (21%)	27 (19%)	130 (21%)	129 (16%)	23 (23%)	388 (13%)	1078 (16%)
History of atrial fibrillation	55 (19%)	60 (18%)	113 (18%)	188 (24%)	37 (26%)	97 (16%)	108 (13%)	42 (42%)	914 (30%)	1614 (24%)
Antiplatelet use	78 (27%)	93 (28%)	87 (14%)	196 (25%)	59 (42%)	211 (34%)	201 (24%)	30 (30%)	1306 (43%)	2261 (33%)
Weight (kg)	78 (17)	78 (19)	74 (12)	75 (14)	80 (20)	79 (18)	78 (15)	75 (19)	72 (15)	75 (16)
Systolic blood pressure (mmHg)	154 (21)	152 (21)	154 (23)	152 (21)	152 (24)	152 (21)	153 (21)	148 (19)	155 (24)	154 (22)
Diastolic blood pressure (mmHg)	85 (13)	85 (14)	87 (13)	84 (13)	81 (14)	82 (14)	84 (14)	78 (13)	82 (15)	83 (14)


Categorical data presented as n (%), continuous data presented as mean (SD). NINDS=National Institute of Neurological Disorders and Stroke; ECASS=European Cooperative Acute Stroke Study; ATLANTIS=Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke; EPITHET=Echoplanar Imaging Thrombolytic Evaluation Trial; IST=International Stroke Trial. *In IST-3, 244 patients had their baseline NIHSS score predicted from other measurements recorded at their baseline assessment. Ignoring these patients, the numbers of IST-3 patients in each category of baseline NIHSS score above would be 385, 972, 531, 559 and 344 respectively.

Figure 1: The effect within 7 days of alteplase on three types of intracerebral haemorrhage (ICH): parenchymal haemorrhage type 2 (PH-2), SITS-MOST haemorrhage, and fatal ICH



* Estimated from a trial-stratified logistic regression model adjusted only for treatment allocation


Figure 2: The effect of alteplase on SITS–MOST intracerebral haemorrhage at 24 to 36 hrs by time to treatment, age and stroke severity



* For each of the three baseline characteristics shown, the odds ratio subgroup estimates shown are derived from a single trial–stratified logistic regression model which allows for separate estimation of the OR in each of the subgroups after adjustment for the other two baseline characteristics (but not possible interactions with those characteristics). The overall effect in all patients (indicated by the open diamond) is the trial–stratified logistic regression estimate adjusted only for treatment allocation.

The absolute excess risk (and its 95% CI) for each subgroup is estimated by applying the odds ratio seen among all randomised patients (or its confidence limits) to the average expected risk among control–allocated patients for that subgroup (estimated from a logistic regression model among all participants adjusted for trial, treatment allocation, the subgroup of interest and average levels of the other two baseline characteristics).


Figure 3: Effect of alteplase on: a) deaths preceded by clinically significant intracerebral haemorrhage (SITS–MOST or fatal haemorrhage within 7 days); and b) all other deaths, within the first 90 days




Average hazard ratio estimated by Cox proportional hazards regression stratified by trial, with adjustment only for treatment allocation

Figure 4: Expected proportions in each category of modified Rankin score at 3—6 months, with or without alteplase given within 4.5 hours of symptom onset (mean 3 hrs 20 min)


a) NIHSS 0–4 (n=666)




b) NIHSS 5–10 (n=2533)




c) NIHSS 11–15 (n=1602)



d) NIHSS 16–21 (n=1333)




e) NIHSS 22+ (n=622)



mRS 0/1='Excellent' outcome; In IST-3, 125 (4.1%) patients died between 3 and 6 months. For comparability of mRS 6 between IST-3 and the other trials (which had 3 month mRS), these patients were reassigned an mRS of 5 for this analysis.

Figure 5: EXPECTED stroke outcome at 3–6 months for groups of patients: i) not treated with alteplase; ii) treated with alteplase within 3 hours of stroke onset; and iii) treated with alteplase between 3 and 4.5 hours after stroke onset.




Each 10 x 10 grid represents 100 hypothetical patients who have experienced a stroke with severity 0–4 NIHSS points (top row), 5–15 points (middle row) or 16+ points (bottom row). Each circle in each grid represents a single patient with the colour of the circle reflecting their expected mRS outcome at 3–6 months if: a) not given alteplase (left column); b) given alteplase within 3 hours (middle column); or c) given alteplase between 3 and 4.5 hours (right column).

Webmaterial: What are the risks of intracerebral haemorrhage due to alteplase after acute ischaemic stroke? Results from an individual patient data meta-analysis of randomised trials


Webfigures		Pg
1	Effect of alteplase on intracerebral haemorrhage in each trial	2
2	Treatment-modifying effects of time to treatment, age and stroke severity on parenchymal haemorrhage type 2 within 7 days	3
3	Treatment-modifying effects of time to treatment, age and stroke severity on SITS-MOST intracerebral haemorrhage at 24-36 hours	4
4	Treatment-modifying effects of time to treatment, age and stroke severity on fatal intracerebral haemorrhage within 7 days	5
5	The effect of alteplase on parenchymal haemorrhage type 2 within 7 days by time to treatment, age and stroke severity	6
6	The effect of alteplase on fatal intracerebral haemorrhage within 7 days by time to treatment, age and stroke severity	7
7a	Expected proportions in each category of modified Rankin score at 3—6 months, with or without alteplase given within 3 hours of symptom onset (mean 2 hrs 20 min)	8
7b	Expected proportions in each category of modified Rankin score at 3—6 months, with or without alteplase given within 3-4.5 hours of symptom onset (mean 2 hrs 50 min)	9
8	Effect of alteplase on: a) deaths preceded by PH-2 haemorrhage; and b) all other deaths, within the first 90 days	10

Webfigure 1: Effect of alteplase on intracerebral haemorrhage in each trial



Where estimable, individual trial estimates above correspond to the simple odds ratio and its 95% confidence interval. The summary diamonds, and their 95% CIs, are derived from trial-stratified logistic regression models (which allow trials with zero events in the control arm to contribute information). There was no evidence that the proportional effect of allocation to alteplase on ICH differed between the placebo-controlled trials and IST-3 ($p=0.76$ for PH-2 within 7 days, $p=0.72$ for SITS-MOST haemorrhage and $p=0.61$ for fatal ICH within 7 days). Nor was there any evidence of significant heterogeneity between all 9 trials (test for trial-by-treatment interaction: $p=0.57$ for PH-2 within days, $p=0.87$ for SITS-MOST haemorrhage and $p=0.88$ for fatal ICH within 7 days).


Webfigure 2: Treatment-modifying effects of time to treatment, age and stroke severity on parenchymal haemorrhage type 2 within 7 days



The solid line on each plot shows how the estimated odds ratio associated with allocation to alteplase varies with, respectively, time, age and baseline NIHSS, so its slope provides a test for interaction between that characteristic and allocation to alteplase. Each panel is adjusted for treatment delay, age, and baseline NIHSS (as linear main effects), and all three treatment-interaction terms (ie, all three panels derive from the same regression model).

The odds ratio in each panel corresponds to patients with AVERAGE levels of the other 2 baseline characteristics. The OR for alteplase was 6.26 at the mean values of age (71 years), NIHSS (12 points) and time to treatment (4 hours). The significance of each interaction, as well as the global test of all interactions, is tested by comparing the change in deviance between two nested models that differ only by the interaction term(s) (ie, the likelihood ratio test).


Webfigure 3: Treatment-modifying effects of time to treatment, age and stroke severity on SITS-MOST intracerebral haemorrhage at 24–36 hours



The solid line on each plot shows how the estimated odds ratio associated with allocation to alteplase varies with, respectively, time, age and baseline NIHSS, so its slope provides a test for interaction between that characteristic and allocation to alteplase. Each panel is adjusted for treatment delay, age, and baseline NIHSS (as linear main effects), and all three treatment–interaction terms (ie, all three panels derive from the same regression model).

The odds ratio in each panel corresponds to patients with AVERAGE levels of the other 2 baseline characteristics. The OR for alteplase was 6.94 at the mean values of age (71 years), NIHSS (12 points) and time to treatment (4 hours). The significance of each interaction, as well as the global test of all interactions, is tested by comparing the change in deviance between two nested models that differ only by the interaction term(s) (ie, the likelihood ratio test).


Webfigure 4: Treatment-modifying effects of time to treatment, age and stroke severity on fatal intracerebral haemorrhage within 7 days



The solid line on each plot shows how the estimated odds ratio associated with allocation to alteplase varies with, respectively, time, age and baseline NIHSS, so its slope provides a test for interaction between that characteristic and allocation to alteplase. Each panel is adjusted for treatment delay, age, and baseline NIHSS (as linear main effects), and all three treatment-interaction terms (ie, all three panels derive from the same regression model).

The odds ratio in each panel corresponds to patients with AVERAGE levels of the other 2 baseline characteristics. The OR for alteplase was 6.63 at the mean values of age (71 years), NIHSS (12 points) and time to treatment (4 hours). The significance of each interaction, as well as the global test of all interactions, is tested by comparing the change in deviance between two nested models that differ only by the interaction term(s) (ie, the likelihood ratio test).


Webfigure 5: The effect of alteplase on parenchymal haemorrhage type 2 within 7 days by time to treatment, age and stroke severity



* For each of the three baseline characteristics shown, the odds ratio subgroup estimates shown are derived from a single trial–stratified logistic regression model which allows for separate estimation of the OR in each of the subgroups after adjustment for the other two baseline characteristics (but not possible interactions with those characteristics). The overall effect in all patients (indicated by the open diamond) is the trial–stratified logistic regression estimate adjusted only for treatment allocation.

The absolute excess risk (and its 95% CI) for each subgroup is estimated by applying the odds ratio seen among all randomised patients (or its confidence limits) to the average expected risk among control–allocated patients for that subgroup (estimated from a logistic regression model among all participants adjusted for trial, treatment allocation, the subgroup of interest and average levels of the other two baseline characteristics).

Webfigure 6: The effect of alteplase on fatal intracerebral haemorrhage within 7 days by time to treatment, age and stroke severity




* For each of the three baseline characteristics shown, the odds ratio subgroup estimates shown are derived from a single trial–stratified logistic regression model which allows for separate estimation of the OR in each of the subgroups after adjustment for the other two baseline characteristics (but not possible interactions with those characteristics). The overall effect in all patients (indicated by the open diamond) is the trial–stratified logistic regression estimate adjusted only for treatment allocation.


The absolute excess risk (and its 95% CI) for each subgroup is estimated by applying the odds ratio seen among all randomised patients (or its confidence limits) to the average expected risk among control–allocated patients for that subgroup (estimated from a logistic regression model among all participants adjusted for trial, treatment allocation, the subgroup of interest and average levels of the other two baseline characteristics).

Webfigure 7a: Expected proportions in each category of modified Rankin score at 3—6 months, with or without alteplase given within 3 hours of symptom onset (mean 2 hrs 20 min)


a) NIHSS 0–4 (n=666)




b) NIHSS 5–10 (n=2533)




c) NIHSS 11–15 (n=1602)



d) NIHSS 16–21 (n=1333)




e) NIHSS 22+ (n=622)




mRS 0/1='Excellent' outcome; In IST-3, 125 (4.1%) patients died between 3 and 6 months. For comparability of mRS 6 between IST-3 and the other trials (which had 3 month mRS), these patients were reassigned an mRS of 5 for this analysis.

Webfigure 7b: Expected proportions in each category of modified Rankin score at 3—6 months, with or without alteplase given within 3–4.5 hours of symptom onset (mean 3 hrs 50 min)


a) NIHSS 0–4 (n=666)




b) NIHSS 5–10 (n=2533)




c) NIHSS 11–15 (n=1602)



d) NIHSS 16–21 (n=1333)




e) NIHSS 22+ (n=622)



mRS 0/1='Excellent' outcome; In IST-3, 125 (4.1%) patients died between 3 and 6 months. For comparability of mRS 6 between IST-3 and the other trials (which had 3 month mRS), these patients were reassigned an mRS of 5 for this analysis.

Webfigure 8: Effect of alteplase on: a) deaths preceded by PH-2 haemorrhage; and b) all other deaths, within the first 90 days



Average hazard ratio estimated by Cox proportional hazards regression stratified by trial, with adjustment only for treatment allocation